Stoke Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
STOK$27.21-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed consolidated statements of operations and comprehensive (loss) income
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue | $6,229 | $158,569 |
| Operating expenses: | ||
| Research and development | 39,673 | 32,676 |
| Sales, general and administrative | 19,974 | 14,653 |
| Total operating expenses | 59,647 | 47,329 |
| (Loss) income from operations | (53,418) | 111,240 |
| Other income (expense): | ||
| Interest income (expense), net | 3,397 | 2,889 |
| Other income | 18 | 28 |
| Total other income (expense) | 3,415 | 2,917 |
| (Loss) income before income taxes | $(50,003) | $114,157 |
| Provision for income taxes | — | 1,278 |
| Net (loss) income | $(50,003) | $112,879 |
| Net (loss) income per share: | ||
| Basic | $(0.79) | $1.95 |
| Diluted | (0.79) | 1.90 |
| Weighted-average common shares outstanding: | ||
| Basic | 63,063,507 | 57,862,674 |
| Diluted | 63,063,507 | 59,398,600 |
| Comprehensive (loss) income: | ||
| Net (loss) income | $(50,003) | $112,879 |
| Other comprehensive (loss) gain: | ||
| Unrealized (loss) gain on marketable securities | (658) | 47 |
| Total other comprehensive (loss) gain | $(658) | $47 |
| Comprehensive (loss) income | $(50,661) | $112,926 |
Condensed consolidated statements of stockholders’ equity
| Common Stock · Additionalpaid-in capital · Accumulated other comprehensive gain (loss) · Accumulateddeficit · Total stockholders’equity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | ||||||||||
| Balance as of December 31, 2024 | 54,032,826 | $5 | $719,997 | $(151) | $(490,830) | $229,021 | ||||
| Unrealized gain on marketable securities | — | — | — | 47 | — | 47 | ||||
| Stock-based compensation | — | — | 6,753 | — | — | 6,753 | ||||
| Issuance of common stock upon exercise of stock options | 214,996 | — | 1,004 | — | — | 1,004 | ||||
| Issuance of common stock related to employee stock purchase plan | 39,467 | — | 370 | — | — | 370 | ||||
| Issuance of vested restricted and performance stock units | 308,425 | — | — | — | — | — | ||||
| Net income | — | — | — | — | 112,879 | 112,879 | ||||
| Balance as of March 31, 2025 | 54,595,714 | $5 | $728,124 | $(104) | $(377,951) | $350,074 | ||||
| Balance as of December 31, 2025 | 58,921,999 | $5 | $849,624 | $543 | $(497,715) | $352,457 | ||||
| Unrealized (loss) on marketable securities | — | — | — | (658) | — | (658) | ||||
| Stock-based compensation | — | — | 8,753 | — | — | 8,753 | ||||
| Issuance of common stock upon exercise of stock options | 260,554 | — | 3,205 | — | — | 3,205 | ||||
| Issuance of common stock related to employee stock purchase plan | 46,994 | 465 | — | — | 465 | |||||
| Issuance of vested restricted and performance stock units | 443,786 | — | — | — | — | — | ||||
| Shares sold as part of controlled equity offering sales agreement | 2,567,014 | 1 | 80,657 | — | — | 80,658 | ||||
| Net loss | — | — | — | — | (50,003) | (50,003) | ||||
| Balance as of March 31, 2026 | 62,240,347 | $6 | $942,704 | $(115) | $(547,718) | $394,877 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.